Free Delivery on orders over £29*
Baytril
2.5% Oral Solution » 100ml Bottle

  • 2.5% Oral Solution » 100ml Bottle £29.99
  • 2.5% Solution for Injection » 50ml Bottle £20.50
  • 5% Solution for Injection » 100ml Bottle £43.00
  • 10% Oral Solution » 100ml Bottle £63.49
  • 10% Oral Solution » 1 Litre Bottle £261.49
  • 10% Solution for Injection » 100ml Bottle £73.49
  • Flavour Tablets 15mg » Priced per Tablet £0.70
  • Flavour Tablets 50mg » Priced per Tablet £1.19
  • Flavour Tablets 150mg » Priced per Tablet £2.69
  • Piglet Doser 0.5% » 100ml Bottle £25.00

Selection of 10 products from

£0.70 to £261.49

Description

Baytril is a synthetic, broad spectrum antibiotic used in dogs, cats, rabbits, chickens and other animals. For use in dogs and cats it is normally supplied as Baytril flavour tablets. Baytril can be used in a wide variety of other animals, and for these Baytril Oral Solution is normally best. Baytril has been used very widely in rabbits, guinea pigs, rats, mice, hamsters, as well as many species of bird and reptile. The solution can be added to drinking water, or placed directly in the mouth. If it is placed in drinking water, it should not be in a metal dispenser if possible as this may denature it chemically and reduce its effectiveness. Baytril is also available as an injection or in a doser for use in piglets. Baytril treats a wide variety of bacterial infections of the alimentary, respiratory and urogenital tracts and skin. Where possible the veterinary surgeon should perform sensitivity testing of the bacteria involved before deciding if Baytril is appropriate.

Baytril should not be used in young growing animals as it can have an adverse effect on the cartilage in joints. Overdosing cats can cause eye damage so accurate dosing is important. The usual dose rate is 5mg/kg bodyweight. For full datasheet information of each product, click on its description above.

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

Flavour Tablets 150mg » Priced per Tablet

Baytril Flavour Tablets

Presentation

Baytril Flavour Tablets 15 mg are light brown to brown, slightly marbled, round, planar, tablets containing 15 mg enrofloxacin and 6 mg artificial beef flavour irradiated for oral administration to dogs and cats.

Baytril Flavour Tablets 50 mg and 150 mg are light brown to brown, slightly marbled, round, curved, scored, tablets containing 50 mg or 150 mg enrofloxacin and 12 mg or 42 mg artificial beef flavour irradiated respectively for oral administration to dogs.

Uses

Baytril Flavour Tablets 15 mg

The product is for use in dogs and cats in the treatment of bacterial infections of the alimentary, respiratory and urogenital tracts, skin, secondary wound infections and otitis externa where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

Baytril Flavour Tablets 50 mg and 150 mg

The product is for use in dogs in the treatment of bacterial infections of the alimentary, respiratory and urogenital tracts, skin, secondary wound infections and otitis externa where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

Dosage and administration

Dogs and cats

The dosage rate of enrofloxacin is 5 mg/kg given orally once daily or as a divided dose twice daily for 3 to 10 days with or without food. Treatment may be initiated with Baytril 5% Injection or Baytril 2.5% Injection and maintained with Baytril Flavour Tablets.

The daily dose is achieved as follows:

Cats and small dogs: 1 Baytril Flavour Tablet 15 mg per 3 kg bodyweight

Medium dogs: 1 tablet Baytril Flavour Tablets 50 mg per 10 kg bodyweight

Large dogs: 1 tablet Baytril Flavour Tablets 150 mg per 30 kg bodyweight

Use during pregnancy and lactation

The product may be used safely in pregnant and lactating animals.

Contra-indications, warnings, etc

Baytril Flavour Tablets should not be used for prophylaxis.

Not for use in dogs less than 1 year of age or in exceptionally large breeds of dog with a longer growth period under 18 months of age, as articular cartilage may be affected during the period of rapid growth.

Not recommended for use in cats less than 8 weeks of age.

Do not exceed the recommended dose. In accidental overdose, vomiting, diarrhoea, and CNS/behavioural changes may occur. There is no antidote and treatment should be symptomatic.

Cats: Retinotoxic effects including blindness can occur when the recommended dose is exceeded.

In target animal studies, cats have been shown to suffer ocular damage after receiving doses of more than 15 mg/kg once daily for 21 consecutive days. Doses of 30 mg/kg given once daily for 21 consecutive days have been shown to cause irreversible ocular damage. At 50 mg/kg given once daily for 21 consecutive days, blindness can occur.

Dogs: In dogs enrofloxacin may affect articular cartilage during the period of rapid growth.

Environmental safety

Any unused product or waste material should be disposed of in accordance with national requirements.

Pharmaceutical precautions

Do not store above 25°C. Store in a dry place.

Shelf-life as packaged for sale: 5 years

Further information

Enrofloxacin is a synthetic, broad spectrum antimicrobial substance, belonging to the fluoroquinolone group of antibiotics. ATC Vet Code: QJ01MA90.

Enrofloxacin is bactericidal in action with activity against Gram positive and Gram negative bacteria and mycoplasmas. The mechanism of action of the quinolones is unique among antimicrobials – they act primarily to inhibit bacterial DNA gyrase, an enzyme responsible for controlling the supercoiling of bacterial DNA during replication. Resealing of the double standard helix is inhibited resulting in irreversible degradation of the chromosomal DNA. The fluoroquinolones also possess activity against bacteria in the stationary phase by an alteration of the permeability of the outer membrane phospholipid cell wall.

The pharmacokinetics of enrofloxacin are such that oral and parenteral administration lead to similar serum levels. Enrofloxacin possesses a high distribution volume. Tissue levels 2–3 times higher than that found in the serum have been demonstrated in laboratory animals and target species. Organs in which high levels can be expected are the lungs, liver, kidney, skin, bone, and lymphatic system. Enrofloxacin also distributes into the cerebrospinal fluid, the aqueous humour, and the foetus in pregnant animals.

Legal category

Packaging quantities

Baytril Flavour Tablets 15mg: Silver or white coloured aluminium foil blister or plastic coated aluminium blister strips of 10 light brown unmarked tablets supplied in dispensing cartons containing 100 tablets.

Baytril Flavour Tablets 50 mg and 150 mg: Silver or white coloured aluminium foil blister or plastic coated aluminium blister strips of 10 light brown to brown, scored tablets supplied in dispensing cartons containing 100 tablets.

Marketing Authorisation Number

Baytril Flavour Tablets 15 mg Vm 00010/4081
Baytril Flavour Tablets 50 mg Vm 00010/4082
Baytril Flavour Tablets 150 mg Vm 00010/4083

Flavour Tablets 15mg » Priced per Tablet

SUMMARY OF PRODUCT CHARACTERISTICS

  1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Baytril Flavour Tablets 15 mg

  1. QUALITATIVE AND QUANTITATIVE COMPOSITION

2.1 Active Constituents mg per tablet Enrofloxacin 15.0

2.2 Relevant Constituents of the Excipients

Artificial beef flavour Irradiated    6.0

For full list of excipients, see section 6.1

  1. PHARMACEUTICAL FORM

Tablet. A light brown to brown, slightly marbled, round, planar tablet for oral administration to dogs and cats.

  1. CLINICAL PARTICULARS

4.1 Target species

Dogs and Cats.

4.2 Indications for use, specifying the target species

The product is for use in dogs and cats in the treatment of bacterial infections of the alimentary, respiratory and urogenital tracts, skin, secondary wound infections and otitis externa where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

4.3 Contraindications

Not for use in dogs less than 1 year of age or in exceptionally large breeds of dog with a longer growth period under 18 months of age, as articular cartilage may be affected during the period of rapid growth. Not recommended for use in cats less than 8 weeks of age. Baytril Flavour Tablets 15 mg should not be used for prophylaxis.

4.4 Special warnings for each target species

Please refer to item 4.3.

Cats: Retinotoxic effects including blindness can occur when the recommended dose is exceeded.

4.5 Special precautions for use

i. Special precautions for use in animals

Do not exceed the recommended dosage

ii. Special precautions to be taken by the person administering the medicinal product to animals

None.

iii. Other precautions

None.

4.6 Adverse reactions (frequency and seriousness)

During the period of rapid growth, enrofloxacin may affect articular cartilage development.

4.7 Use during pregnancy, lactation or lay

The product may be used safely in pregnant and lactating animals.

4.8 Interaction with other medicinal products and other forms of interaction

None known.

4.9 Amount(s) to be administered and administration route

The dosage rate of enrofloxacin is 5 mg/kg given orally once daily or as a divided dose twice daily for 3 to 10 days with or without food. Treatment may be initiated with Baytril 5% Injection or Baytril 2.5% Injection and maintained with Baytril Flavour Tablets.

The daily dose is achieved as follows:-

Cats and small dogs: 1 Baytril Flavour Tablet 15 mg per 3 kg bodyweight.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Do not exceed the recommended dose. In accidental overdose, vomiting, diarrhoea and CNS/behavioural changes may occur. There is no antidote and treatment should be symptomatic.

In target animal studies, cats have been shown to suffer ocular damage after receiving doses of more than 15 mg/kg once daily for 21 consecutive days. Doses of 30 mg/kg given once daily for 21 consecutive days have been shown to cause irreversible ocular damage. At 50 mg/kg given once daily for 21 consecutive days, blindness can occur.

4.11 Withdrawal period(s)

Not applicable

  1. PHARMACOLOGICAL PROPERTIES

Enrofloxacin is a synthetic, broad spectrum antimicrobial substance, belonging to the fluoroquinolone group of antibiotics.

ATC Vet Code: QJ01MA90

5.1 Pharmacodynamics

Enrofloxacin is bactericidal in action with activity against Gram positive and Gram negative bacteria and mycoplasmas. The mechanism of action of the quinolones is unique among antimicrobials – they act primarily to inhibit bacterial DNA gyrase, an enzyme responsible for controlling the supercoiling of bacterial DNA during replication. Resealing of the double standard helix is inhibited resulting in irreversible degradation of the chromosomal DNA. The fluoroquinolones also possess activity against bacteria in the stationary phase by an alteration of the permeability of the outer membrane phospholipid cell wall.

5.2 Pharmacokinetics

The pharmacokinetics of enrofloxacin in dogs and cats are such that oral and parenteral administration leads to similar serum levels. Enrofloxacin possesses a high distribution volume. Tissue levels 2-3 times higher than that found in the serum, have been demonstrated in laboratory animals and target species. Organs in which high levels can be expected are the lungs, liver, kidney, skin, bone and lymphatic system. Enrofloxacin also distributes into the cerebrospinal fluid, the aqueous humour and the foetus in pregnant animals.

  1. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose monohydrate Maize starch Microcrystalline cellulose Polyvidone/Povidone Magnesium stearate Silica colloidal anhydrous Artificial beef flavour Irradiated

6.2 Incompatibilities

None known

6.3 Shelf-life

Shelf-life of the product as packaged for sale: 5 years.

6.4 Special precautions for storage

Do not store above 25ºC. Store in a dry place.

6.5 Nature and composition of immediate packaging

Container material : Aluminium foil blister or plastic coated aluminium blister Container colour : Silver or white coloured Container volume : Strips of 10 light brown unmarked tablets supplied in dispensing cartons containing 100 tablets

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate

Any unused product or waste material should be disposed of in accordance with national requirements.

  1. MARKETING AUTHORISATION HOLDER

UK Only: IE Only: Bayer plc 400 South Oak Way Green Park Reading Berkshire RG2 6AD Bayer Ltd, Animal Health Division, The Atrium, Blackthorn Road, Dublin 18, Ireland 8. MARKETING AUTHORISATION NUMBERS

UK Only: IE Only: Vm 00010/4081 VPA 10021/5/1

  1. DATE OF FIRST AUTHORISATION/LAST RENEWAL OF THE AUTHORISATION

UK Only: IE Only:

Date: 20 May 1992 01 October 1988 Date: 20 May 2007 30 September 2008

  1. DATE OF REVISION OF THE TEXT

UK Only:

May 2017

Approved: 05 May 2017

Flavour Tablets 50mg » Priced per Tablet

Baytril Flavour Tablets

Presentation

Baytril Flavour Tablets 15 mg are light brown to brown, slightly marbled, round, planar, tablets containing 15 mg enrofloxacin and 6 mg artificial beef flavour irradiated for oral administration to dogs and cats.

Baytril Flavour Tablets 50 mg and 150 mg are light brown to brown, slightly marbled, round, curved, scored, tablets containing 50 mg or 150 mg enrofloxacin and 12 mg or 42 mg artificial beef flavour irradiated respectively for oral administration to dogs.

Uses

Baytril Flavour Tablets 15 mg

The product is for use in dogs and cats in the treatment of bacterial infections of the alimentary, respiratory and urogenital tracts, skin, secondary wound infections and otitis externa where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

Baytril Flavour Tablets 50 mg and 150 mg

The product is for use in dogs in the treatment of bacterial infections of the alimentary, respiratory and urogenital tracts, skin, secondary wound infections and otitis externa where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

Dosage and administration

Dogs and cats

The dosage rate of enrofloxacin is 5 mg/kg given orally once daily or as a divided dose twice daily for 3 to 10 days with or without food. Treatment may be initiated with Baytril 5% Injection or Baytril 2.5% Injection and maintained with Baytril Flavour Tablets.

The daily dose is achieved as follows:

Cats and small dogs: 1 Baytril Flavour Tablet 15 mg per 3 kg bodyweight

Medium dogs: 1 tablet Baytril Flavour Tablets 50 mg per 10 kg bodyweight

Large dogs: 1 tablet Baytril Flavour Tablets 150 mg per 30 kg bodyweight

Use during pregnancy and lactation

The product may be used safely in pregnant and lactating animals.

Contra-indications, warnings, etc

Baytril Flavour Tablets should not be used for prophylaxis.

Not for use in dogs less than 1 year of age or in exceptionally large breeds of dog with a longer growth period under 18 months of age, as articular cartilage may be affected during the period of rapid growth.

Not recommended for use in cats less than 8 weeks of age.

Do not exceed the recommended dose. In accidental overdose, vomiting, diarrhoea, and CNS/behavioural changes may occur. There is no antidote and treatment should be symptomatic.

Cats: Retinotoxic effects including blindness can occur when the recommended dose is exceeded.

In target animal studies, cats have been shown to suffer ocular damage after receiving doses of more than 15 mg/kg once daily for 21 consecutive days. Doses of 30 mg/kg given once daily for 21 consecutive days have been shown to cause irreversible ocular damage. At 50 mg/kg given once daily for 21 consecutive days, blindness can occur.

Dogs: In dogs enrofloxacin may affect articular cartilage during the period of rapid growth.

Environmental safety

Any unused product or waste material should be disposed of in accordance with national requirements.

Pharmaceutical precautions

Do not store above 25°C. Store in a dry place.

Shelf-life as packaged for sale: 5 years

Further information

Enrofloxacin is a synthetic, broad spectrum antimicrobial substance, belonging to the fluoroquinolone group of antibiotics. ATC Vet Code: QJ01MA90.

Enrofloxacin is bactericidal in action with activity against Gram positive and Gram negative bacteria and mycoplasmas. The mechanism of action of the quinolones is unique among antimicrobials – they act primarily to inhibit bacterial DNA gyrase, an enzyme responsible for controlling the supercoiling of bacterial DNA during replication. Resealing of the double standard helix is inhibited resulting in irreversible degradation of the chromosomal DNA. The fluoroquinolones also possess activity against bacteria in the stationary phase by an alteration of the permeability of the outer membrane phospholipid cell wall.

The pharmacokinetics of enrofloxacin are such that oral and parenteral administration lead to similar serum levels. Enrofloxacin possesses a high distribution volume. Tissue levels 2–3 times higher than that found in the serum have been demonstrated in laboratory animals and target species. Organs in which high levels can be expected are the lungs, liver, kidney, skin, bone, and lymphatic system. Enrofloxacin also distributes into the cerebrospinal fluid, the aqueous humour, and the foetus in pregnant animals.

Legal category

Packaging quantities

Baytril Flavour Tablets 15mg: Silver or white coloured aluminium foil blister or plastic coated aluminium blister strips of 10 light brown unmarked tablets supplied in dispensing cartons containing 100 tablets.

Baytril Flavour Tablets 50 mg and 150 mg: Silver or white coloured aluminium foil blister or plastic coated aluminium blister strips of 10 light brown to brown, scored tablets supplied in dispensing cartons containing 100 tablets.

Marketing Authorisation Number

Baytril Flavour Tablets 15 mg Vm 00010/4081
Baytril Flavour Tablets 50 mg Vm 00010/4082
Baytril Flavour Tablets 150 mg Vm 00010/4083

5% Solution for Injection » 100ml Bottle

Baytril 25 mg/ml Solution for Injection

Presentation

A clear light yellow solution for injection containing 25 mg/ml enrofloxacin as active substance and 30 mg/ml n-Butyl alcohol as excipient.

Uses

Dogs

Treatment of infections of the alimentary, respiratory and urogenital tracts (including prostatitis, adjunctive antibiotic therapy for pyometra), skin and wound infections, otitis (externa/media) caused by enrofloxacin susceptible strains of Staphylococcus spp., Escherichia coli, Pasteurella spp., Klebsiella spp., Bordetella spp., Pseudomonas spp. and Proteus spp.

Cats

Treatment of infections of the alimentary, respiratory and urogenital tracts (as adjunctive antibiotic therapy for pyometra), skin and wound infections, caused by enrofloxacin susceptible strains of Staphylococcus spp., Escherichia coli, Pasteurella spp., Klebsiella spp., Bordetella spp., Pseudomonas spp. and Proteus spp.

Pigs (piglets)

Treatment of infections of the respiratory tract caused by enrofloxacin susceptible strains of Pasteurella multocida, Mycoplasma spp., Actinobacillus pleuropneumoniae.

Treatment of infections of the alimentary tract caused by enrofloxacin susceptible strains of Escherichia coli.

Treatment of septicaemia caused by enrofloxacin susceptible strains of Escherichia coli.

Rabbits

Treatment of infections of the alimentary and respiratory tracts caused by enrofloxacin susceptible strains of Escherichia coli, Pasteurella multocida and Staphylococcus spp.

Treatment of skin and wound infections caused by enrofloxacin susceptible strains of Staphylococcus aureus.

Rodents, reptiles and ornamental birds

Treatment of infections of the alimentary and respiratory tracts where clinical experience, if possible, supported by susceptibility testing of the causal organism, indicates enrofloxacin as the substance of choice.

Dosage and administration

To ensure a correct dosage, body weight (bw) should be determined as accurately as possible to avoid underdosing.

Repeated injections should be made at different injection sites.

5 mg of enrofloxacin/kg bw, corresponding to 1 ml/5 kg bw, daily by subcutaneous injection for up to 5 days.

Treatment may be initiated with injectable product and maintained with enrofloxacin tablets. Duration of treatment should be based on the duration of treatment approved for the appropriate indication in the product information of the tablet product.

2.5 mg of enrofloxacin/kg bw, corresponding to 1 ml/10 kg bw, once daily by intramuscular injection for 3 days.

For alimentary tract infection or septicaemia caused by Escherichia coli: 5 mg of enrofloxacin/kg of bw, corresponding to 2 ml/10 kg bw, once daily by intramuscular injection for 3 days.

In pigs, the injection should be made in the neck at the ear base.

Not more than 3 ml should be administered at one intramuscular injection site.

10 mg/kg bw, corresponding to 2 ml/5 kg bw, once daily by subcutaneous injection for 5 to 10 consecutive days.

10 mg/kg bw, corresponding to 0.4 ml/kg bw, once daily by subcutaneous injection for 5 to 10 consecutive days. If necessary, depending on the severity of clinical signs, this dosage can be doubled.

Reptiles are ectothermic, relying on external heat sources to maintain their body temperature at the optimum level for correct function of all body systems. Metabolism of substances and activity of the immune system are, thus, critically dependent on the body temperature. Therefore, the veterinarian must be aware of the correct temperature requirements of the respective reptile species and the hydration status of the individual patient. Furthermore, it has to be considered that large differences exist in the pharmacokinetic behaviour of enrofloxacin among different species, which additionally will influence the decision about the correct dosage of Baytril 25 mg/ml solution for injection. Therefore, the recommendations made here can only be used as a starting point for individual dose setting.

5–10 mg/kg bw, corresponding to 0.2–0.4 ml/kg bw, once daily by intramuscular injection for 5 consecutive days.

An extension of the treatment interval to 48 hours may be necessary in individual cases. In complicated infections, higher dosages and longer treatment courses may be necessary. The presence of the renal portal system in reptiles means it is prudent to administer substances in the front half of the body wherever possible.

20 mg/kg bw, corresponding to 0.8 ml/kg bw, once daily by intramuscular injection for 5 to 10 consecutive days. In case of complicated infections higher doses may be necessary.

Laboratory studies in rats and rabbits have not produced any evidence of teratogenic effects but have shown evidence of foetotoxic effects at maternotoxic doses.

Mammals

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only accordingly to the benefit/risk assessment by the responsible veterinarian.

Birds and reptiles

The safety of the veterinary medicinal product has not been established during lay. Use only accordingly to the benefit/risk assessment by the responsible veterinarian.

Contra-indications, warnings, etc

Do not use in the case of known hypersensitivity to fluoroquinolones or to any of the excipients.

Do not use in animals that are epileptic or suffer from seizures since enrofloxacin may cause CNS stimulation.

Do not use in young dogs during their growth, i.e. in small breeds of dogs less than 8 months of age, in large breeds of dogs less than 12 months of age, in giant breeds of dogs less than 18 months of age.

Do not use in cats less than 8 weeks of age.

Official and local antimicrobial policies should be taken into account when the product is used.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.

Whenever possible fluoroquinolones should only be used based on susceptibility testing.

Use of the product including use deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to enrofloxacin and may decrease the effectiveness of treatment with all fluoroquinolones due to the potential for cross-resistance.

Special caution should be taken when using enrofloxacin in animals with impaired renal function.

Special caution should be taken when using enrofloxacin in cats because higher doses than recommended can cause retinal damage and blindness

Digestive tract disorders (e.g. diarrhoea) may occur in very rare cases. These signs are generally mild and transient.

Local reactions at the injection site:

In pigs, after intramuscular administration of the product, inflammatory reactions may occur. They may persist up to 28 days after the injection.

In dogs, a moderate and transient local reaction (such as oedema) may occur.

In rabbits, reactions (from reddening to ulcerative lesions with deep loss of tissue), may occur. They may persist at least up to 17 days after the injection.

In reptiles and birds, muscle bruising may occur in very rare cases.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)

- common (more than 1 but less than 10 animals in 100 animals)

- uncommon (more than 1 but less than 10 animals in 1,000 animals)

- rare (more than 1 but less than 10 animals in 10,000 animals)

- very rare (less than 1 animal in 10,000 animals, including isolated reports).

In cases of accidental overdose digestive tract disorders (e.g. vomiting, diarrhoea) and neurological disorders may occur.

In pigs, no adverse effects were reported after the administration of 5 times the recommended dose.

Cats have been shown to suffer ocular damage after receiving doses of more than 15 mg/kg once daily for 21 consecutive days. Doses of 30 mg/kg given once daily for 21 consecutive days have been shown to cause irreversible ocular damage. At 50 mg/kg given once daily for 21 consecutive days, blindness can occur.

In dogs, rabbits, small rodents, reptiles and birds, overdose has not been documented.

In accidental overdose there is no antidote and treatment should be symptomatic.

Do not use enrofloxacin concomitantly with antimicrobial substances acting antagonistically to quinolones (e.g. macrolides, tetracyclines or phenicols).

Do not use concurrently with theophylline as the elimination of theophylline may be delayed.

Care should be taken during the concomitant use of flunixin and enrofloxacin in dogs to avoid adverse drug reactions. The decrease in drug clearances as a result of co-administration of flunixin and enrofloxacin indicates that these substances interact during the elimination phase. Thus, in dogs, the co-administration of enrofloxacin and flunixin increased the AUC and the elimination half-life of flunixin and increased the elimination half-life and reduced the Cmax of enrofloxacin.

In countries where feeding of fallen stock to scavenger bird populations is permitted as a conservation measure (see Commission Decision 2003/322/EC), the possible risk to hatching success should be considered before feeding carcasses of livestock recently treated with this product.

User Safety

People with known hypersensitivity to fluoroquinolones should avoid any contact with the product.

Avoid skin and eye contact. Wash any splashes from skin or eyes immediately with water.

Wash hands after use. Do not eat, drink or smoke whilst handling the product.

Care should be taken to avoid accidental self-injection. If accidental self-injection occurs seek medical advice immediately.

Withdrawal periods

Pigs: Meat and offal: 13 days.Rabbits: Meat and offal: 6 days.

Do not use in birds intended for human consumption.

Environmental Safety

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Pharmaceutical precautions

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

Shelf life of the veterinary product as packaged for sale: 4 years.

Shelf life after the first opening of the immediate packaging: 28 days.

Do not refrigerate or freeze.

Legal category

Packaging quantities

50ml brown glass (type I) vials with a chlorobutyl polytetrafluoroethylene (PTFE) stopper and with a flip-off cap with aluminium case and plastic flip-off button.

Further information

Pharmacotherapeutic group: Antibacterials for systemic use, fluoroquinolones.

ATCvet code: QJ01MA90.

Two enzymes essential in DNA replication and transcription, DNA gyrase and topoisomerase IV, have been identified as the molecular targets of fluoroquinolones. Target inhibition is caused by non-covalent binding of fluoroquinolone molecules to these enzymes. Replication forks and translational complexes cannot proceed beyond such enzyme-DNA-fluoroquinolone complexes, and inhibition of DNA and mRNA synthesis triggers events resulting in a rapid, drug concentration-dependent killing of pathogenic bacteria. The mode of action of enrofloxacin is bactericidal and bactericidal activity is concentration dependent.

Enrofloxacin is active against many Gram-negative bacteria such as Escherichia coli, Klebsiella spp., Actinobacillus pleuropneumoniae, Pasteurella spp. (e.g. Pasteurella multocida), Bordetella spp., Proteus spp., Pseudomonas spp., against Gram-positive bacteria such as Staphylococcus spp. (e.g. Staphylococcus aureus) and against Mycoplasma spp. at the recommended therapeutic doses.

Resistance to fluoroquinolones has been reported to arise from five sources, (i) point mutations in the genes encoding for DNA gyrase and/or topoisomerase IV leading to alterations of the respective enzyme, (ii) alterations of drug permeability in Gram-negative bacteria, (iii) efflux mechanisms, (iv) plasmid mediated resistance and (v) gyrase protecting proteins. All mechanisms lead to a reduced susceptibility of the bacteria to fluoroquinolones. Cross-resistance within the fluoroquinolone class of antimicrobials is common.

Enrofloxacin is rapidly absorbed after parenteral injection. Bioavailability is high (approximately 100% in pigs) with a low to moderate plasma protein binding (approximately from 20 to 50%). Enrofloxacin is metabolised to the active substance ciprofloxacin at approximately 40% in dogs and less than 10% in cats and pigs.

African Grey Parrots’ serum ciprofloxacin concentrations were 3–78% of the enrofloxacin dose, with an increasing ciprofloxacin/enrofloxacin ratio with multiple doses.

Enrofloxacin and ciprofloxacin distribute well into all target tissues, e.g. lung, kidney, skin, and liver, reaching 2- to 3-fold higher concentrations than in plasma. Parent substance and active metabolite are cleared from the body via urine and faeces.

Accumulation in plasma does not occur following a treatment interval of 24 h.

Marketing Authorisation Number

Vm00010/4075

10% Oral Solution » 100ml Bottle

Baytril 10% Oral Solution

Presentation

Clear yellowish oral solution for use in drinking water containing, as active ingredient, enrofloxacin. One ml of Baytril 10% Oral Solution contains 100mg enrofloxacin and 14mg benzyl alcohol

Uses

Baytril 10% Oral Solution is indicated for use in chickens, turkeys and rabbits, for the treatment of infections caused by the following bacteria susceptible to enrofloxacin:

Chickens:

Mycoplasma gallisepticum,

Mycoplasma synoviae,

Avibacterium paragallinarum,

Pasteurella multocida.

Turkeys:

Mycoplasma gallisepticum,

Mycoplasma synoviae,

Pasteurella multocida.

Rabbits:

For the treatment of infectious diseases due to Pasteurella multocida and bacterial enteritis due to infection with E.coli.

Enrofloxacin should be used where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the active substance of choice.

Dosage and administration

Chickens and turkeys:

10 mg enrofloxacin/kg bodyweight per day for 3-5 consecutive days.

Treatment for 3-5 consecutive days; for 5 consecutive days in mixed infections and chronic progressive forms. If no clinical improvement is achieved within 2-3 days, alternative antimicrobial therapy should be considered based on susceptibility testing.

Via the drinking water. Always make sure that the entire dose offered has been consumed. The medicated water should be made up fresh each day just before it is offered to the animals. The drinking water must be medicated throughout the treatment period, and no other water source should be available. Determine the bodyweight of the birds as accurately as possible in order to avoid underdosing.

Use only fresh pre-solutions, prepared every day before start of treatment. Pumping systems should be checked constantly to assure proper medication. Empty the water system and fill it with medicated water before starting the treatment.

Calculate the daily quantity (ml) of Baytril 10% Oral Solution required for treatment period as follows:

Total number of birds x Average body weight in kg x 0.1= Total volume (ml) per day

Baytril 10% Oral Solution may be put directly into the header tank or introduced via a water proportioner pump.

Rabbits:

10 mg/kg bodyweight per day for 5 consecutive days.

Calculate the daily quantity (ml) of Baytril 10% Oral Solution required for treatment period as follows:

Total number of rabbits x Average body weight in kg x 0.1= Total volume (ml) per day

Via the drinking water. Always make sure that the entire dose offered has been consumed. The medicated water should be made up fresh each day just before it is offered to the animals. The drinking water must be medicated throughout the treatment period, and no other water source should be available. Determine the bodyweight of the animals as accurately as possible in order to avoid underdosing.

Use during pregnancy, lactation or lay

Do not use in laying hens producing eggs for human consumption.

Do not administer to layer replacement birds within 14 days of coming into lay

Contra-indications, warnings, etc

Do not use for prophylaxis.

Do not use when resistance/ cross-resistance to (fluoro)quinolones is known to occur in the flock intended for treatment.

Do not use in the case of known hypersensitivity to the active substance, other (fluoro)quinolones or to any of the excipients.

Treatment of Mycoplasma spp infections may not eradicate the organism.

Official and local antimicrobial policies should be taken into account when the product is used.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.

Since enrofloxacin was first authorised for use in poultry, there has been widespread reduction in susceptibility of E.coli to fluoroquinolones and emergence of resistant organisms. Resistance has also been reported in Mycoplasma synoviae in the EU.

Whenever possible, fluoroquinolones should only be used based on susceptibility testing.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

In vitro, an antagonism was shown, when combining fluoroquinolones with bacteriostatic antimicrobial agents such as macrolides or tetracyclines and phenicols. The simultaneous application of substances containing aluminium or magnesium can impair the absorption of enrofloxacin.

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

No adverse clinical symptoms were observed in chickens and turkeys treated respectively with doses up to 10 and 6 times higher than the therapy dose.

The use of fluoroquinolones during the growth phase combined with a marked and prolonged increase in the intake of drinking water, and hence active ingredient, possibly due to high temperatures, may potentially be associated with damage of the articular cartilage.

Those with known hypersensitivity to (fluoro)quinolones should avoid contact with this product.

Avoid contact with skin and eyes.

Rinse any splashes from skin or eyes immediately with water.

Wash hands and exposed skin after use.

Do not eat, drink or smoke while using the product.

Chickens: Meat and offal: 7 days.

Turkeys: Meat and offal: 13 days.

Rabbits: Meat and offal: 3 days.

Not authorised for use in birds producing eggs for human consumption.

Do not administer to layer replacement birds within 14 days of coming into lay.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Pharmaceutical precautions

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

This veterinary medicinal product does not require any special storage conditions.

Shelf life of the veterinary medicinal product as packaged for sale: 4 years

Shelf-life after first opening the immediate packaging: 12 weeks

Shelf-life after dilution or reconstitution according to directions: 24 hours

Further information

Pharmacotherapeutic group: quinolone and quinoxaline antibacterials, fluoroquinolones. ATCVet Code QJ01MA90.

Two enzymes essential in DNA replication and transcription, DNA gyrase and topoisomerase IV, have been identified as the molecular targets of fluoroquinolones. They modulate the topological state of DNA through cleaving and resealing reactions. Initially, both strands of the DNA double helix are cleaved. Then, a distant segment of DNA is passed through this break before the strands are resealed. Target inhibition is caused by non-covalent binding of fluoroquinolone molecules to an intermediate state in this sequence of reactions, in which DNA is cleaved, but both strands are retained covalently attached to the enzymes. Replication forks and translational complexes cannot proceed beyond such enzyme-DNA-fluoroquinolone complexes, and inhibition of DNA and mRNA synthesis triggers events resulting in a rapid, drug concentration-dependant killing of pathogenic bacteria.

Enrofloxacin is active against many Gram-negative bacteria, against Gram-positive bacteria and Mycoplasma spp.

In vitro susceptibility has been shown in strains of (i) Gram-negative species such as Pasteurella multocida and Avibacterium (Haemophilus) paragallinarum and (ii) Mycoplasma gallisepticum and Mycoplasma synoviae.

Resistance to fluoroquinolones has been reported to arise from five sources, (i) point mutations in the genes encoding for DNA gyrase and/or topoisomerase IV leading to alterations of the respective enzyme, (ii) alterations of drug permeability in Gram-negative bacteria, (iii) efflux mechanisms, (iv) plasmid mediated resistance and (v) gyrase protecting proteins. All mechanisms lead to a reduced susceptibility of the bacteria to fluoroquinolones. Cross-resistance within the fluoroquinolone class of antimicrobials is common.

Enrofloxacin administered via drinking water to poultry is rapidly and very well absorbed with a bioavailability of approx. 90%. Maximum plasma concentrations of 2 mg/L are reached within 1.5 hours after a single bolus dose rate of 10 mg/kg body weight, with a total systemic availability of 14.4 mg.hr/L. Enrofloxacin is eliminated from the body with a total body clearance of 10.3 ml/min.kg. If dosed as continuous drinking water medication (multiple dosing) steady-state concentrations of 0.5 mg (turkeys) to 0.8 mg (chicken) enrofloxacin per litre are achieved. A high mean volume of distribution (5 L/kg) indicated good tissue penetration of enrofloxacin. Concentrations in target tissues like lungs, liver, kidney, intestine and muscle tissue, exceed plasma concentrations by far. In poultry enrofloxacin is poorly metabolised to its active metabolite ciprofloxacin (approximately 5%). Enrofloxacin is eliminated from the body at a half-life of 6 hours. Protein binding in poultry is approximately 25%.

Legal category

Packaging quantities

100 ml and 1,000 ml high density polyethylene (HDPE) bottles with an HDPE insert and a polypropylene screw closure.

The containers are provided with a graduated polypropylene measuring cup.

Marketing Authorisation Number

Vm 00010/4077

10% Oral Solution » 1 Litre Bottle

Baytril 10% Oral Solution

Presentation

Clear yellowish oral solution for use in drinking water containing, as active ingredient, enrofloxacin. One ml of Baytril 10% Oral Solution contains 100mg enrofloxacin and 14mg benzyl alcohol

Uses

Baytril 10% Oral Solution is indicated for use in chickens, turkeys and rabbits, for the treatment of infections caused by the following bacteria susceptible to enrofloxacin:

Chickens:

Mycoplasma gallisepticum,

Mycoplasma synoviae,

Avibacterium paragallinarum,

Pasteurella multocida.

Turkeys:

Mycoplasma gallisepticum,

Mycoplasma synoviae,

Pasteurella multocida.

Rabbits:

For the treatment of infectious diseases due to Pasteurella multocida and bacterial enteritis due to infection with E.coli.

Enrofloxacin should be used where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the active substance of choice.

Dosage and administration

Chickens and turkeys:

10 mg enrofloxacin/kg bodyweight per day for 3-5 consecutive days.

Treatment for 3-5 consecutive days; for 5 consecutive days in mixed infections and chronic progressive forms. If no clinical improvement is achieved within 2-3 days, alternative antimicrobial therapy should be considered based on susceptibility testing.

Via the drinking water. Always make sure that the entire dose offered has been consumed. The medicated water should be made up fresh each day just before it is offered to the animals. The drinking water must be medicated throughout the treatment period, and no other water source should be available. Determine the bodyweight of the birds as accurately as possible in order to avoid underdosing.

Use only fresh pre-solutions, prepared every day before start of treatment. Pumping systems should be checked constantly to assure proper medication. Empty the water system and fill it with medicated water before starting the treatment.

Calculate the daily quantity (ml) of Baytril 10% Oral Solution required for treatment period as follows:

Total number of birds x Average body weight in kg x 0.1= Total volume (ml) per day

Baytril 10% Oral Solution may be put directly into the header tank or introduced via a water proportioner pump.

Rabbits:

10 mg/kg bodyweight per day for 5 consecutive days.

Calculate the daily quantity (ml) of Baytril 10% Oral Solution required for treatment period as follows:

Total number of rabbits x Average body weight in kg x 0.1= Total volume (ml) per day

Via the drinking water. Always make sure that the entire dose offered has been consumed. The medicated water should be made up fresh each day just before it is offered to the animals. The drinking water must be medicated throughout the treatment period, and no other water source should be available. Determine the bodyweight of the animals as accurately as possible in order to avoid underdosing.

Use during pregnancy, lactation or lay

Do not use in laying hens producing eggs for human consumption.

Do not administer to layer replacement birds within 14 days of coming into lay

Contra-indications, warnings, etc

Do not use for prophylaxis.

Do not use when resistance/ cross-resistance to (fluoro)quinolones is known to occur in the flock intended for treatment.

Do not use in the case of known hypersensitivity to the active substance, other (fluoro)quinolones or to any of the excipients.

Treatment of Mycoplasma spp infections may not eradicate the organism.

Official and local antimicrobial policies should be taken into account when the product is used.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.

Since enrofloxacin was first authorised for use in poultry, there has been widespread reduction in susceptibility of E.coli to fluoroquinolones and emergence of resistant organisms. Resistance has also been reported in Mycoplasma synoviae in the EU.

Whenever possible, fluoroquinolones should only be used based on susceptibility testing.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

In vitro, an antagonism was shown, when combining fluoroquinolones with bacteriostatic antimicrobial agents such as macrolides or tetracyclines and phenicols. The simultaneous application of substances containing aluminium or magnesium can impair the absorption of enrofloxacin.

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

No adverse clinical symptoms were observed in chickens and turkeys treated respectively with doses up to 10 and 6 times higher than the therapy dose.

The use of fluoroquinolones during the growth phase combined with a marked and prolonged increase in the intake of drinking water, and hence active ingredient, possibly due to high temperatures, may potentially be associated with damage of the articular cartilage.

Those with known hypersensitivity to (fluoro)quinolones should avoid contact with this product.

Avoid contact with skin and eyes.

Rinse any splashes from skin or eyes immediately with water.

Wash hands and exposed skin after use.

Do not eat, drink or smoke while using the product.

Chickens: Meat and offal: 7 days.

Turkeys: Meat and offal: 13 days.

Rabbits: Meat and offal: 3 days.

Not authorised for use in birds producing eggs for human consumption.

Do not administer to layer replacement birds within 14 days of coming into lay.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Pharmaceutical precautions

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

This veterinary medicinal product does not require any special storage conditions.

Shelf life of the veterinary medicinal product as packaged for sale: 4 years

Shelf-life after first opening the immediate packaging: 12 weeks

Shelf-life after dilution or reconstitution according to directions: 24 hours

Further information

Pharmacotherapeutic group: quinolone and quinoxaline antibacterials, fluoroquinolones. ATCVet Code QJ01MA90.

Two enzymes essential in DNA replication and transcription, DNA gyrase and topoisomerase IV, have been identified as the molecular targets of fluoroquinolones. They modulate the topological state of DNA through cleaving and resealing reactions. Initially, both strands of the DNA double helix are cleaved. Then, a distant segment of DNA is passed through this break before the strands are resealed. Target inhibition is caused by non-covalent binding of fluoroquinolone molecules to an intermediate state in this sequence of reactions, in which DNA is cleaved, but both strands are retained covalently attached to the enzymes. Replication forks and translational complexes cannot proceed beyond such enzyme-DNA-fluoroquinolone complexes, and inhibition of DNA and mRNA synthesis triggers events resulting in a rapid, drug concentration-dependant killing of pathogenic bacteria.

Enrofloxacin is active against many Gram-negative bacteria, against Gram-positive bacteria and Mycoplasma spp.

In vitro susceptibility has been shown in strains of (i) Gram-negative species such as Pasteurella multocida and Avibacterium (Haemophilus) paragallinarum and (ii) Mycoplasma gallisepticum and Mycoplasma synoviae.

Resistance to fluoroquinolones has been reported to arise from five sources, (i) point mutations in the genes encoding for DNA gyrase and/or topoisomerase IV leading to alterations of the respective enzyme, (ii) alterations of drug permeability in Gram-negative bacteria, (iii) efflux mechanisms, (iv) plasmid mediated resistance and (v) gyrase protecting proteins. All mechanisms lead to a reduced susceptibility of the bacteria to fluoroquinolones. Cross-resistance within the fluoroquinolone class of antimicrobials is common.

Enrofloxacin administered via drinking water to poultry is rapidly and very well absorbed with a bioavailability of approx. 90%. Maximum plasma concentrations of 2 mg/L are reached within 1.5 hours after a single bolus dose rate of 10 mg/kg body weight, with a total systemic availability of 14.4 mg.hr/L. Enrofloxacin is eliminated from the body with a total body clearance of 10.3 ml/min.kg. If dosed as continuous drinking water medication (multiple dosing) steady-state concentrations of 0.5 mg (turkeys) to 0.8 mg (chicken) enrofloxacin per litre are achieved. A high mean volume of distribution (5 L/kg) indicated good tissue penetration of enrofloxacin. Concentrations in target tissues like lungs, liver, kidney, intestine and muscle tissue, exceed plasma concentrations by far. In poultry enrofloxacin is poorly metabolised to its active metabolite ciprofloxacin (approximately 5%). Enrofloxacin is eliminated from the body at a half-life of 6 hours. Protein binding in poultry is approximately 25%.

Legal category

Packaging quantities

100 ml and 1,000 ml high density polyethylene (HDPE) bottles with an HDPE insert and a polypropylene screw closure.

The containers are provided with a graduated polypropylene measuring cup.

Marketing Authorisation Number

Vm 00010/4077

2.5% Oral Solution » 100ml Bottle

Baytril 2.5% Oral Solution

Presentation

An oral solution containing 25 mg/ml enrofloxacin as active ingredient and 14 mg/ml benzyl alcohol as excipient.

Uses

Baytril 2.5% Oral Solution is for use in calves for the treatment of infections of the alimentary and respiratory tracts of bacterial or mycoplasmal origin (e.g. pasteurellosis, mycoplasmosis, coli-bacillosis and salmonellosis), where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

Baytril 2.5% Oral Solution may also be used in exotic animals (small mammals, reptiles and avian species) for the treatment of bacterial infections of the alimentary and respiratory tracts where clinical experience, supported where possible by sensitivity testing of the causal organism, indicates enrofloxacin as the drug of choice.

Dosage and administration

Administer via the milk, milk replacer, electrolyte solution or water. The dose rate is 2.5 mg per kg body weight (5 ml per 50 kg) daily for 3 days. This rate may be doubled to 5 mg per kg (10 ml per 50 kg) for 5 days for salmonellosis and complicated respiratory disease. Medicated fluids should be made up immediately prior to provision on a daily basis.

See Table 1.

The dose rates given below are for guidance only. Veterinary surgeons are advised to contact the company prior to use to discuss the particulars of each individual case.

For direct administration by gavage, dilutions of 1 part product to 4 parts water are recommended. If the product is to be given via the drinking water, concentrations of between 50 and 200 ppm should be considered as suitable working dilutions; concentrations in excess of 250 ppm should be avoided as precipitation may occur. The dilution should be made on a daily basis, immediately prior to provision, preferably in a glass container. The use of a 0.5 ml (100 unit) insulin syringe should be considered for the withdrawal of very small volumes of the product and to facilitate dilution prior to administration. Medicated fluids should be made up immediately prior to provision on a daily basis.

Table 1: Dosage for Baytril 2.5% Oral Solution
Species | Dosage | Route | Dose Frequency | Treatment period
Small mammals | 5 mg enrofloxacin per kg bodyweight(0.2 ml/kg bw) | Orally diluted in water | Twice daily | 7 days
Reptiles | 5 mg enrofloxacin per kg bodyweight(0.2 ml/kg bw) | Orally diluted in water | 24-48 hour intervals | 6 days
Birds(excluding chickens and turkeys) | 10 mg enrofloxacin per kg bodyweight(0.4 ml/kg bw) | Orally diluted in water | Twice daily | 7 days
Baytril 2.5% Oral Solution Table

Use during pregnancy and lactation

In the absence of data on its use in some exotic species, caution should be used when prescribing during these periods and a careful risk/benefit assessment made.

Contra-indications, warnings, etc

The product should not be used for prophylaxis.

Exotic animals: Consult the Technical Services Department of Bayer prior to use.

Official and local antimicrobal policies should be taken into account when the product is used.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.

Wherever possible, fluoroquinolones should only be used based on susceptibility testing.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

During the period of rapid growth, enrofloxacin may affect articular cartilage.

Do not exceed the recommended dose. In accidental overdose there is no antidote and treatment should be symptomatic.

Not for use in poultry (chickens and turkeys).

User safety

Wear impervious gloves when handling the product.

Wash any splashes from skin or eyes immediately with water.

Wash hands and exposed skin after use.

Do not eat, drink or smoke whilst using the product.

Withdrawal period(s)

Calves: Meat: 8 days

Not for use in exotic animals or birds intended for human consumption.

Environmental Safety

Any unused product or waste material should be disposed of in accordance with national requirements.

Pharmaceutical precautions

Do not store above 25°C. Store in a dry place.

Shelf-life of the unopened container: 3 years.

Shelf-life of the broached container: Following withdrawal of the first dose, use the product within 28 days. Discard unused material.

Shelf-life of the diluted product: Any medicated liquid remaining 24 hours after preparation must be discarded.

Further information

Enrofloxacin is a synthetic, broad spectrum antimicrobial substance, belonging to the fluoroquinolone group of antibiotics. ATC Vet Code: QJ01MA90

Enrofloxacin is bactericidal in action with activity against Gram positive and Gram negative bacteria and mycoplasmas. The mechanism of action of the quinolones is unique among antimicrobials - they act primarily to inhibit bacterial DNA gyrase, an enzyme responsible for controlling the supercoiling of bacterial DNA during replication. Resealing of the double stranded helix is inhibited resulting in irreversible degradation of the chromosomal DNA. The fluoroquinolones also possess activity against bacteria in the stationary phase by an alteration of the permeability of the outer membrane phospholipid cell wall.

The pharmacokinetics of enrofloxacin are such that both oral and parenteral administration leads to similar serum levels. Enrofloxacin possesses a high distribution volume. Tissue levels 2-3 times higher than found in the serum, have been demonstrated in laboratory animals and target species. Organs in which high levels can be expected are the lungs, liver, kidney, skin, bone and lymphatic system. Enrofloxacin also distributes into the cerebrospinal fluid, the aqueous humour and the foetus in pregnant animals.

Legal category

Packaging quantities

White high density polyethylene bottles with a polypropylene screw cap containing 100 ml.

Marketing Authorisation Number

Vm 00010/4078

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews (2)

Q & A

There are currently no questions for Baytril - be the first to ask one!